Emprumapimod
CAS No. 765914-60-1
Emprumapimod( —— )
Catalog No. M35693 CAS No. 765914-60-1
Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 400 | Get Quote |
|
| 5MG | 511 | Get Quote |
|
| 10MG | 816 | Get Quote |
|
| 50MG | 1582 | Get Quote |
|
| 100MG | 2088 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEmprumapimod
-
NoteResearch use only, not for human use.
-
Brief DescriptionEmprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.
-
DescriptionEmprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain.
-
In Vitro——
-
In VivoAnimal Model:LmnaH222P/H222P mice were Dosage:30 mg/kg Administration:Administered orally by gavage starting when mice were 16 weeks of age and continuing until 20 weeks of age Result:There were significant increases in LVEDD and LVESD as well as a decrease in FS, a parameter directly proportional to the LV ejection fraction.
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38 MAPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number765914-60-1
-
Formula Weight473.52
-
Molecular FormulaC24H29F2N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (211.18 mM; Ultrasonic )
-
SMILESC(C(C)C)N1C=2C(=CC(OC3=C(F)C=C(F)C=C3)=C(C(N[C@@H](CCN(C)C)C(N)=O)=O)C2)C=N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Kamebakaurine
Kamebakaurin has the ability to protect the liver from APAP-induced hepatotoxicity, presumably by both inhibiting the inflammatory response and oxidative stress.
-
PAF (C16)
PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.
-
SB 202190
SB 202190 (SB202190, SB-202190) is a potent inhibitor p38α and p38β with IC50 of 50 nM and 100 nM respectively.
Cart
sales@molnova.com